Christopher O'Donnell
InvestorVice President, WWBD / Partner at Pfizer Venture Investments · Board director at Strata Oncology
Connecticut
Writes $100K – $15M checks · typically $10M
Find your path to Christopher
60 people in our graph share verified history with Christopher — schools, employers, funds. One of them is your warm intro.
Richard ChesworthunlockedChristopher: together at Kymera Therapeutics (2020)
Christopher: together at Arkuda Therapeutics
Christopher: together at Strata Oncology
×3Christopher: together at Arrakis Therapeutics
About
Christopher O'Donnell is a Partner and Vice President at Pfizer Ventures and a Board Member at Cartography Biosciences. He holds a B.S. in Chemistry from the University of Illinois and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison, with postdoctoral experience in synthetic chemistry at UC Irvine. At Pfizer, where he joined in 1999, O'Donnell has held roles as medicinal chemist, project leader, and manager, contributing to the discovery of clinical candidates in neuroscience programs and building the Antibody Drug Conjugate chemistry group in 2010, which has nominated fourteen conjugates for clinical development with seven entering clinical trials; he subsequently established the Applied Synthesis Technologies group in 2017 and is an author on over 50 publications and inventor on more than 20 patents.
Board director at Strata Oncology
Intro paths
→
In turn, Christopher can intro founders to Strata Oncology's investors below.
Strata Oncology's investors · 5
Co-founders at Strata Oncology
DR
Daniel RhodesExecutive Officer, Director
Experience
- Cartography BiosciencesBoard Membercurrent2026 — present
- TRexBioBoard Membercurrent2026 — present
- Enlaza TherapeuticsBoard Observercurrent2024 — presentLa Jolla, California
- Arrakis TherapeuticsMember Board Of Directorscurrent2021 — present
- PfizerVice President - Business Development and Partner, Pfizer Venturescurrent2022 — presentNew York, United States
- PfizerPartner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovationcurrent2020 — present
- PfizerExecutive Director, External Sciences & Innovation & Principal, Pfizer Ventures2018 — 2020
- PfizerExecutive Director, Applied Synthesis Technology2016 — 2018Groton, CT
- PfizerExecutive Director, Oncology Medicinal Chemistry2015 — 2016Groton, CT
- PfizerSenior Director, Oncology Medicinal Chemistry2010 — 2015Groton, CT
- PfizerSenior Director, Neuroscience Medicinal Chemistry2009 — 2010Groton, CT
- PfizerDirector, Neuroscience Medicinal Chemistry2007 — 2008Groton, CT
- PfizerAssociate Director, Neuroscience Medicinal Chemistry2006 — 2007Groton, CT
- PfizerProject Team Lead, Neuroscience Medicinal Chemistry2006 — 2007Groton, CT
- PfizerSenior Principal Scientist, CNS Medicinal Chemistry2004 — 2006Groton, CT
- PfizerSenior Research Scientist, CNS Medicinal Chemistry2001 — 2004Groton, CT
- PfizerResearch Scientist, CNS Medicinal Chemistry1999 — 2001Groton, CT
- Pyxis OncologyTechnical Advisory Boardcurrent2022 — present
- TRIANA BiomedicinesMember Board Of Directorscurrent2022 — present
- MindImmune Therapeutics, Inc.Member Board of Directorscurrent2022 — presentSouth Kingston, RI
- Kestrel TherapeuticsBoard Observercurrent2021 — present
- Incendia TherapeuticsBoard of Directorscurrent2021 — present
- STORM Therapeutics LimitedBoard Of Directorscurrent2019 — present
- Strata OncologyBoard of Directorscurrent2021 — present
- Strata OncologyBoard observer2018 — 2021
- Arkuda TherapeuticsBoard Of Directors2019 — 2025
- Adapsyn BiosciencesBoard Of Directors2019 — 2024
- Pyxis OncologyMember Board Of Directors2021
- BioAtla LLCBoard Observer2019 — 2020
- Kymera TherapeuticsBoard Of Directors2019 — 2020
- Kymera TherapeuticsBoard Observer2018 — 2019
- Petra Pharma CorporationBoard Observer2019 — 2020
- Morphic TherapeuticBoard Observer2018 — 2019
Skills & more
Board LevelBoard GovernanceDirectorshipBoard level experienceMedicinal Chemistry45Drug Discovery46Pharmaceutical Industry20Biopharmaceuticals8Oncology13Drug Development24Drug Design19Lifesciences8
+12 more
BiotechnologyClinical DevelopmentLead ChangeADMEDMPKOrganic ChemistryHPLCChromatographyLife SciencesBiomarkersLC-MSDrug MetabolismFrom Christopher's professional profile.
Colleagues at Pfizer Venture Investments
Ama Amoah
Finance Director, Business Development at Pfizer Venture Investments
Andrew J. Muratore
Vice President & Chief Counsel, M&A and Licensing at Pfizer Venture Investments
Anthony Barry
Executive Director, WWBD / Partner at Pfizer Venture Investments
Artem Smirnov
Partner at Xora
Boyoon Choi
Senior Corporate Counsel at Pfizer Venture Investments
Carlos Murillo
Presidente Pfizer España at Taram Capital
Gillian Akai
Senior Vice President, General Counsel, Communications and Corporate Secretary at Maple Leaf Foods strategic venture activity
Irena Melnikova
Executive Director, WWBD / Partner at Pfizer Venture Investments
Network4
Scott SandellScout
Executive Chairman & Chief Investment Officer at NEA
Ben LingScout
General Partner at Bling Capital
Jerry YangScout
Founder & Co-Founder at AME Cloud Ventures
Rana Al-Hallaq
Partner at Pfizer Venture Investments
Investors connected to Christopher in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Christopher O'Donnell?
- Christopher O'Donnell is a Partner and Vice President at Pfizer Ventures and a Board Member at Cartography Biosciences. He holds a B.S. in Chemistry from the University of Illinois and a Ph.D. in Organic Chemistry from the University of Wisconsin, Madison, with postdoctoral experience in synthetic chemistry at UC Irvine. At Pfizer, where he joined in 1999, O'Donnell has held roles as medicinal chemist, project leader, and manager, contributing to the discovery of clinical candidates in neuroscience programs and building the Antibody Drug Conjugate chemistry group in 2010, which has nominated fourteen conjugates for clinical development with seven entering clinical trials; he subsequently established the Applied Synthesis Technologies group in 2017 and is an author on over 50 publications and inventor on more than 20 patents.
- Where does Christopher O'Donnell work?
- Christopher O'Donnell is Vice President, WWBD / Partner at Pfizer Venture Investments and Board director at Strata Oncology.
- What check size does Christopher O'Donnell write?
- Christopher O'Donnell typically writes checks of $100K – $15M.
- Where did Christopher O'Donnell go to school?
- Christopher O'Donnell studied at UC Irvine (Post Doc, Organic Chemistry); University of Wisconsin-Madison (PhD, Organic Chemistry); University of Illinois Urbana-Champaign (Bachelor of Science - BS, Organic Chemistry).
Same school
Also attended UC Irvine205
Christian BuergerPortfolio Development at Intel CapitalJonathan GiegCommunity Manager at Pantera CapitalRyan LaurinManaging Director at Marlin Equity PartnersChristopher WestSenior Legal Counsel at Qualcomm VenturesPascal KroteePrincipal, Ph.D. at RiverVest Venture PartnersZack IsaacsonVenture Partner at Rackhouse Venture Management Lp
+ 199 more
Also attended University of Wisconsin-Madison455
Zhenyu TangInvestment Director at Intel CapitalDougAdvisor at Clear VenturesDan RuchPartner at Rho VenturesJoe HayesInvestor at LightbankGeorge RobertsInvestor at OpenView Venture PartnersBret L. BostwickMD, FAAP, FACMG, Venture Advisor at Breyer Capital
+ 449 more
Also attended University of Illinois Urbana-Champaign691
Max LevchinCo-founder of PayPal; founder, chairman & CEO of Affirm; partner at SciFi VCLuke NosekCo-founder of PayPal; co-founder of GigafundSundeep PeechuGeneral Partner at Felicis VenturesDeep NisharInvestment Team at General CatalystPrashant ShahPartner at Monta Vista CapitalNoorPartner at Clear Ventures
+ 685 more
Shared employers
Also worked at Arrakis Therapeutics8
Alan WaltsVenture Partner at Advent Life SciencesNeil KubicaTherapeutics at GENERAL INCEPTIONRichard GasterManaging Partner at venBio PartnersNikolaInvestment Committee Member at ACF InvestorsNikola TrbovicManaging Partner at SV Health InvestorsJakob LovenPartner at Nextech Invest
+ 2 more
Also worked at MindImmune Therapeutics, Inc.2
Also worked at STORM Therapeutics Limited6
Robert TansleyPartner at Cambridge Innovation CapitalMichael AnsteyPartner at Cambridge Innovation CapitalChristine MartinHead of Ventures at University of Cambridge EnterpriseHakan GokerManaging Director at M VenturesSeiji MiyaharaSenior Investment Director at Taiho Ventures, LLCTony KouzaridesVenture Partner / Resident Knight at Fifty Years
